Intended for non-insulin-using individuals aged 18 and older, the Libre Rio system is said to be the first over-the-counter CGM system in the US with a glucose measurement range of 40mg/dL-400mg/dL.

In 2024, Abbott obtained FDA approvals for two new over-the-counter CGMs called Lingo and Libre Rio, which are based on Libre’s technology. The technology is now used by more than 6 million ...

Earlier, in June 2024, the U.S. FDA cleared Abbott’s – Libre Rio and Lingo – new over-the-counter glucose monitoring devices. This should also aid the overall diabetes portfolio sales.

Abbott (NYSE: ABT) will report its Q3 2024 results on Wednesday, ... Earlier, in June 2024, the U.S. FDA cleared Abbott’s – Libre Rio and Lingo – new over-the-counter glucose monitoring devices.

Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, ... Lingo and Libre Rio, another of Abbott's devices, ...

In June 2024, the FDA approved Abbott's two new over-the-counter continuous glucose monitoring (CGM) systems: Lingo and Libre Rio. Abbott has been expanding their product offerings in the CGM market.

In June, Abbott announced FDA approval for two new over-the-counter continuous glucose monitoring systems: Lingo and Libre Rio. Sales growth was led by double-digit growth in Diabetes Care ...

In 2024, Abbott obtained FDA approvals for two new over-the-counter CGMs called Lingo and Libre Rio, which are based on Libre’s technology. The technology is now used by more than 6 million ...